#Palbociclib is a selective cyclin-dependent #kinases 4 and 6 (CDK4/6) inhibitor.
Cyclin D1 and CDK4/6 are downstream of signaling pathways, which lead to cellular proliferation.
#Palbociclib reduces proliferation of #breastcancer cells by preventing G1 to S phase cell cycle progression.
Indications:
– Treatment of adult patients with hormone receptor #(HR)-positive, human epidermal growth factor receptor 2 #(HER2)-negative advanced or metastatic breast cancer in combination with:
• an aromatase inhibitor as initial endocrine-based therapy in postmenopausal women or in men,
• Fulvestrant in patients with disease progression following endocrine therapy.
As a pioneer in the field of top-selling #oncologydrugs, #NanoDaru launched this product in the local market in 2018, with trade name of “#PALBOCAP”.
Over the past 4 years, many patients have received this medicine at an absolutely reasonable price which was way lower than the originator.
Having the positive feedback of PALBOCAP on Iranian patients and as an ever-lasting responsibility, NanoDaru decided to start the process of #exporting this product which is classified as one of the top 20 drugs in terms of #globals #sales in 2020 with more than $5 billion.
As always, #ZIMA as the sole company in charge of exporting the pharmaceutical product of #NanoDaru, managed to register PALBOCAP in #Syria, #Iraq, #Pakistan and #Ecuador and it is under the registration procedure in more than 8 other countries such as #Malaysia, the #Philippines, #Russia, #Sri Lanka and etc.
As a reminder for Breast Cancer Awareness Month which is dedicated for global awareness, we are proudly trying our best to deliver hope to the patient community by making PALBOCAP available for anyone in need all around the world.
